164 related articles for article (PubMed ID: 26731315)
1. BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranofin.
Oommen D; Yiannakis D; Jha AN
Mutat Res; 2016; 784-785():8-15. PubMed ID: 26731315
[TBL] [Abstract][Full Text] [Related]
2. Linking genotoxicity and cytotoxicity with membrane fluidity: A comparative study in ovarian cancer cell lines following exposure to auranofin.
Oommen D; Dodd NJ; Yiannakis D; Moyeed R; Jha AN
Mutat Res Genet Toxicol Environ Mutagen; 2016 Oct; 809():43-49. PubMed ID: 27692298
[TBL] [Abstract][Full Text] [Related]
3. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.
May T; Yang J; Shoni M; Liu S; He H; Gali R; Ng SK; Crum C; Berkowitz RS; Ng SW
Neoplasia; 2013 Jun; 15(6):600-8. PubMed ID: 23730208
[TBL] [Abstract][Full Text] [Related]
5. Reactive oxygen species regulate FSH-induced expression of vascular endothelial growth factor via Nrf2 and HIF1α signaling in human epithelial ovarian cancer.
Zhang Z; Wang Q; Ma J; Yi X; Zhu Y; Xi X; Feng Y; Jin Z
Oncol Rep; 2013 Apr; 29(4):1429-34. PubMed ID: 23404377
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
7. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer treatment in mutation carriers/BRCAness.
Lorusso D; Perotto S
Minerva Ginecol; 2016 Oct; 68(5):566-78. PubMed ID: 26785283
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
10. Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells.
Hearn JM; Romero-Canelón I; Munro AF; Fu Y; Pizarro AM; Garnett MJ; McDermott U; Carragher NO; Sadler PJ
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3800-5. PubMed ID: 26162681
[TBL] [Abstract][Full Text] [Related]
11. Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer.
Pradjatmo H; Dasuki D; Anwar M; Mubarika S; Harijadi
Asian Pac J Cancer Prev; 2014; 15(21):9479-85. PubMed ID: 25422243
[TBL] [Abstract][Full Text] [Related]
12. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
[TBL] [Abstract][Full Text] [Related]
13. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival.
Gorrini C; Baniasadi PS; Harris IS; Silvester J; Inoue S; Snow B; Joshi PA; Wakeham A; Molyneux SD; Martin B; Bouwman P; Cescon DW; Elia AJ; Winterton-Perks Z; Cruickshank J; Brenner D; Tseng A; Musgrave M; Berman HK; Khokha R; Jonkers J; Mak TW; Gauthier ML
J Exp Med; 2013 Jul; 210(8):1529-44. PubMed ID: 23857982
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
Lee YK; Park NH; Lee H
Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.
Marzano C; Gandin V; Folda A; Scutari G; Bindoli A; Rigobello MP
Free Radic Biol Med; 2007 Mar; 42(6):872-81. PubMed ID: 17320769
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions.
Wang Y; Wang Y; Wei L; Hong S; Zhao M; Zhang X; Zheng W
J Ovarian Res; 2017 Mar; 10(1):12. PubMed ID: 28270171
[TBL] [Abstract][Full Text] [Related]
19. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
Murai J
Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
[TBL] [Abstract][Full Text] [Related]
20. Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53.
Park SH; Lee JH; Berek JS; Hu MC
Int J Oncol; 2014 Oct; 45(4):1691-8. PubMed ID: 25096914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
